Rock Springs Capital
Rock Springs Capital is an investment company located in Baltimore, Maryland. Its advisory activities include management services to
Business Model: B2B
Revenue: $9.7M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Rock Springs Capital Information
Geographic Data
Address: 650 S Exeter St
City: Baltimore
State: MD
Zip: 21202
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$823M
Social
Crunchbase
Metrics
5,414,657Website Global Rank
1,710Website Monthly Traffic
Twitter Followers
Description
Rock Springs Capital is an investment company located in Baltimore, Maryland. Its advisory activities include management services to security portfolios and portfolio management for businesses or institutional clients.
Contact Phone:
+14102200129
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2018 | Mirum Pharmaceuticals | Series A | 120M |
| 7/2016 | Ardelyx | Post-IPO Equity | 0 |
| 3/2017 | Spero Therapeutics | Series C | 51.7M |
| 7/2021 | Vedanta Biosciences | Series D | 0 |
| 5/2014 | Coherus Biosciences | Series C | 54.7M |
| 6/2018 | Kaleido | Series C | 101M |
| 12/2014 | Ascendis Pharma | Series D | 60M |
| 7/2021 | MiRXES | Series C | 0 |
| 12/2015 | Clearside Biomedical | Series C | 20M |
| 11/2016 | Biohaven Pharmaceutical | Venture Round | 80M |
| 7/2021 | Imperative Care | Series D | 0 |
| 10/2021 | Honor | Series E | 70M |
| 12/2020 | Reneo Pharmaceuticals | Series B | 0 |
| 5/2015 | BeiGene | Series B | 97M |
| 10/2022 | immatics biotechnologies | Post-IPO Equity | 0 |
| 5/2014 | Spark Therapeutics | Series B | 72.8M |
| 1/2022 | AvengeBio | Series A | 0 |
| 12/2019 | Imperative Care | Series C | 0 |
| 7/2017 | Vets First Choice | Private Equity Round | 223M |
| 10/2015 | Audentes Therapeutics | Series C | 65M |
| 4/2015 | Mirna Therapeutics | Series D | 0 |
| 12/2018 | Vedanta Biosciences | Series C | 0 |
| 9/2015 | Aclaris Therapeutics | Series C | 40M |
| 7/2022 | Gossamer Bio | Post-IPO Equity | 0 |
| 10/2021 | Patina | Series A | 50M |
| 4/2019 | Fusion Pharmaceuticals | Series B | 0 |
| 12/2017 | Aptinyx | Series B | 70M |
| 6/2015 | Ardelyx | Post-IPO Equity | 77.8M |
| 5/2020 | Pulmonx | Equity | 66M |
| 8/2017 | Homology Medicines | Series B | 83.5M |
| 7/2021 | dMed | Series C | 0 |
| 2/2021 | Xilio Therapeutics | Series C | 95M |
| 7/2020 | Bolt Biotherapeutics | Series C | 93.5M |
| 10/2020 | Honor | Series D | 140M |
| 1/2021 | Verve Therapeutics | Series B | 94M |
| 3/2015 | Aeglea BioTherapeutics | Series B | 44M |
| 8/2021 | Vigil Neuroscience | Series B | 0 |
| 5/2021 | Caris Life Sciences | Private Equity Round | 0 |
| 4/2019 | Inozyme | Series A | 67.4M |
| 9/2015 | Corvus Pharmaceuticals | Series B | 75M |
| 7/2020 | Cerevel Therapeutics | Post-IPO Equity | 0 |
| 1/2018 | Braeburn | Debt Financing | 0 |
| 2/2015 | Chiasma | Series E | 70M |
| 8/2020 | Freenome | Series C | 270M |
| 12/2014 | Sagimet Biosciences | Series D | 28.5M |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 12/2020 | Cullinan Oncology | Series C | 131.2M |
| 1/2021 | Biomea Fusion | Series A | 56M |
| 9/2018 | Galera Therapeutics | Series C | 70M |
| 4/2015 | Dimension Therapeutics | Series B | 65M |
| 10/2022 | Treeline Biosciences | Series A | 261.3M |
| 12/2021 | Freenome | Series D | 300M |
| 1/2022 | Simcha Therapeutics | Series B | 40M |
| 12/2017 | Allakos | Series B | 100M |
| 6/2015 | Clementia Pharmaceuticals | Venture Round | 0 |
| 2/2023 | Spruce Biosciences | Post-IPO Equity | 0 |
| 6/2020 | Everest Medicines | Series C | 310M |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 7/2015 | Translate Bio | Series B | 0 |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 1/2021 | Affinivax | Series C | 226M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 2/2022 | MiRXES | Series C | 0 |
| 6/2015 | Advanced Accelerator Applications | Venture Round | 25.7M |
| 6/2021 | Apollo Therapeutics | Venture Round | 139.4M |
| 8/2022 | Kymera Therapeutics | Post-IPO Equity | 150M |
| 7/2022 | Immunocore | Post-IPO Equity | 0 |
| 6/2016 | Vedanta Biosciences | Private Equity Round | 0 |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 2/2020 | Spruce Biosciences | Series B | 88M |
| 9/2021 | Disc Medicine | Series B | 90M |
| 2/2023 | Hemab | Series B | 0 |
| 9/2014 | Adaptimmune | Series A | 0 |
| 9/2020 | ESCAPE Bio | Venture Round | 73M |
| 8/2022 | Disc Medicine | Post-IPO Equity | 0 |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 7/2020 | Kindbody | Series B | 0 |
| 3/2015 | aTyr Pharma | Series E | 76M |
| 3/2019 | Imara | Series B | 0 |
| 9/2015 | AveXis | Series D | 65M |
| 11/2020 | Acumen Pharmaceuticals | Series B | 0 |
| 2/2017 | Bristol Myers Squibb | Post-IPO Equity | 80M |
| 5/2020 | Atea | Series D | 215M |
| 11/2017 | resTORbio | Series A | 40M |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 2/2021 | Sagimet Biosciences | Venture Round | 0 |
| 9/2018 | PhaseBio Pharmaceuticals | Series D | 0 |
| 10/2014 | Invitae | Series F | 0 |
| 5/2021 | BioTheryX | Series E | 92M |
| 3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
| 4/2015 | Merus | Series C | 79.1M |
| 3/2021 | Aura Biosciences | Venture Round | 0 |
| 8/2014 | Civitas Therapeutics | Series C | 0 |
| 11/2014 | Nivalis Therapeutics | Venture Round | 30M |
| 5/2016 | G1 Therapeutics | Series C | 0 |
| 3/2015 | Mersana Therapeutics | Series B | 35M |
| 2/2021 | Personal Genome Diagnostics | Series C | 0 |
| 8/2014 | Dermira | Series C | 51M |
| 11/2018 | Aprea | Series C | 0 |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 6/2020 | Athira Pharma | Series B | 85M |
| 8/2020 | Chinook Therapeutics | Private Placement | 106M |
| 3/2020 | Kymera Therapeutics | Series C | 102M |
| 3/2020 | Immunocore | Series B | 0 |
| 12/2020 | Genesis Therapeutics | Series A | 52M |
| 6/2021 | Kindbody | Series C | 0 |
| 5/2015 | Adaptive Biotechnologies | Series F | 195M |
| 6/2017 | Zai Lab | Series C | 30M |
| 6/2016 | Mersana Therapeutics | Series C | 33M |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 11/2013 | TriVascular | Series E | 0 |
| 4/2014 | Adverum Biotechnologies | Series B | 55M |
| 7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
| 4/2021 | Theseus Pharmaceuticals | Series B | 0 |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 4/2018 | Innovent Biologics | Series E | 150M |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 6/2021 | Synthekine | Series B | 0 |
| 7/2020 | New Horizon Health | Series E | 30M |
| 11/2015 | ObsEva | Series B | 58.9M |
| 7/2021 | Clinipace | Venture Round | 0 |
| 9/2020 | Flame Biosciences | Venture Round | 100M |
| 9/2015 | Proteostasis Therapeutics | Series B | 37M |
| 5/2017 | Synlogic | Series C | 42M |
| 12/2021 | EQRx | Post-IPO Equity | 0 |
| 7/2015 | Ra Pharmaceuticals | Series B | 58.5M |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 1/2021 | Delfi Diagnostics | Series A | 0 |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 7/2022 | Immunocore | Post-IPO Equity | 0 |
| 7/2022 | Gossamer Bio | Post-IPO Equity | 0 |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 2/2022 | MiRXES | Series C | 0 |
| 1/2022 | Simcha Therapeutics | Series B | 0 |
| 1/2022 | AvengeBio | Series A | 0 |
| 12/2021 | EQRx | Post-IPO Equity | 0 |
| 12/2021 | Freenome | Series D | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
